Together, these results suggest that IL-1 blockade using anakinra could overcome erlotinib resistance in HNSCC cells in vivo but has no effect on erlotinib efficacy in ES-HNSCC cells. The gene discussed is IL1A; the disease is head and neck squamous cell carcinoma.